Experimental pill daraxonrasib nearly doubles survival time in advanced pancreatic cancer patients
By
Lauran Neergaard
FeedBagel synthesis
· 3 sourcesA daily experimental pill called daraxonrasib nearly doubled survival time in patients with advanced pancreatic cancer during a clinical trial, researchers reported. The drug blocks a mutated KRAS protein that fuels tumor growth in over 90% of pancreatic cancer cases, according to coverage on bsky. Hacker News noted that experts at the world's largest cancer conference hailed the drug as a "gamechanger" and one of the biggest breakthroughs in decades. Patients taking the pill lived a median of 13.2 months compared to 6.7 months for those on chemotherapy, with fewer severe side effects, though it is not a cure.
A weekday bagel. Dependable, satisfying, no fuss.
Summary
A novel experimental pill called daraxonrasib has shown promise in extending survival for patients with advanced pancreatic cancer. The drug blocks a mutated protein (KRAS) that fuels tumor growth in over 90% of pancreatic cancer cases. Researchers reported that the daily pills nearly doubled survival time, marking a significant step forward in treating one of the deadliest cancers, though it is not a cure.
Key quotes
· 2 pulledWhile not curing the cancer, it is a very large step forward
A novel pill helped people with advanced pancreatic cancer live longer, researchers reported Sunday, raising hopes of long-needed better treatments for one of the deadliest types of cancer
You might also wanna read
Daily pill daraxonrasib doubles survival in advanced pancreatic cancer, clinical trial shows
A clinical trial has shown that a daily pill called daraxonrasib can double survival time for patients with advanced pancreatic cancer, one
theguardian.com·2h ago
Spanish Researchers Develop Breakthrough Therapy Protocol for Pancreatic Cancer Treatment
Spanish researchers have developed a new therapy protocol that could revolutionize pancreatic cancer treatment. Pancreatic cancer is notorio
nypost.com·3mo ago